Medolife Rx, Inc., a subsidiary of Quanta (OTC PINK: QNTA), announced positive results from a safety and toxicity study of its drug candidate Escozine®, derived from scorpion peptides, aimed at treating COVID-19. Conducted on over 500 patients in the Dominican Republic, no toxicity was observed, supporting its potential FDA approval. The study’s data will aid regulatory submissions in the U.S. and Dominican Republic. CEO Dr. Arthur Mikaelian emphasized the significance of these results for future clinical development and market entry.
Medolife Rx, Inc., a subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced a significant advancement in its polarization technology with a recent efficacy test showing a remarkable 497% increase in ATP production in primary human fibroblast cells using polarized Kratom compared to its non-polarized counterpart. This validation supports ongoing clinical programs, including the Escozine® treatment for COVID-19 and cancer. The study highlights the potential for increased efficacy of various active pharmaceutical ingredients (APIs) while minimizing side effects and resource use in drug production.
Medolife Rx, a majority-owned subsidiary of Quanta (OTC PINK: QNTA), has announced successful preclinical trial results for its lead drug candidate, Escozine®. The formulation, derived from Rhopalurus princeps scorpion peptides, was proven non-toxic and safe at maximum dosage levels. Conducted on BALB/c mice, the trials showed no significant abnormalities, paving the way for future human trials. The study supports Medolife's FDA drug filing and may facilitate product registration for COVID-19 treatment in the Dominican Republic.
Medolife Rx, a majority-owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), has partnered with CMW Media to enhance its strategic communications. This collaboration aims to elevate Medolife's public profile globally as it progresses in clinical research and expands its nutraceutical product portfolio. Significant milestones include Medolife's acquisition by Quanta, the implementation of proprietary technology, and a distribution agreement in Canada. The partnership is expected to generate investor awareness and communicate Medolife's innovations effectively.
Quanta, Inc. (OTC PINK:QNTA) announced a partnership between its subsidiary, Medolife Rx, and CURE Pharmaceutical on February 7, 2021. This collaboration aims to integrate Medolife's polarization technology with CURE's CUREfilm technology, enhancing their market offerings in pharmaceuticals and nutraceuticals. The agreement will allow Medolife to leverage CURE's licensed manufacturing facility to produce products like a COVID-19 therapeutic and pancreatic cancer drug. This strategic move is expected to significantly boost revenue and expand product capabilities.
Quanta, Inc. (OTC PINK:QNTA) will host a virtual Town Hall on September 10, 2020, at 1:30 PM ET, led by CEO Eric Rice. This event aims to update investors on recent developments and includes a live Q&A session. The public can register to attend via the provided link. Quanta leverages quantum biology technology to enhance plant-based products across various industries including pain management and skincare. The company emphasizes its mission to improve ingredient efficacy and promote sustainable consumption.
Quanta, Inc. (OTC PINK:QNTA) reported its Q2 2020 results, revealing total revenues of $318,000, unchanged from Q2 2019, and a gross margin improvement to 77.7% from 68.2% year-over-year. The net loss slightly decreased to $(1.86 million) or $(0.03) per share, compared to $(1.91 million) or $(0.05) per share in the prior year. Cash used in operations rose to $849,000. The company launched its molequle product line and reported an uptick in sales in July and August, anticipating continued growth despite challenges posed by COVID-19.